NCT00030420 is a Phase 2 clinical trial of Celecoxib in Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Who is sponsoring NCT00030420?

NCT00030420 is sponsored by Barbara Ann Karmanos Cancer Institute.

What drugs are being tested in NCT00030420?

Interventions in NCT00030420: Celecoxib, Docetaxel.

What condition does NCT00030420 study?

NCT00030420 studies Lung Cancer.

Is NCT00030420 still recruiting?

NCT00030420 is currently completed. Last updated 25 April 2013.

Last reviewed 2013-04-25 · How we verify

NCT00030420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy

Completed Phase 2 Last updated 25 April 2013

What this trial tests

Phase 2 trial testing Celecoxib in Lung Cancer in 24 participants. Completed in 1 February 2008.

Timeline

1 October 2001

Primary endpoint
1 May 2004

1 February 2008

Quick facts

Lead sponsor	Barbara Ann Karmanos Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 October 2001
Primary completion	1 May 2004
Estimated completion	1 February 2008
Sites	1 location across United States

Drugs / interventions tested

Celecoxib (celecoxib) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Barbara Ann Karmanos Cancer Institute

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy of combining Celecoxib with Docetaxel
Time frame: Weeks 1 , 2 and 3
Blood levels of VEGF \& PGE2

Sponsor's own description

RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and docetaxel in treating patients who have advanced non-small cell lung cancer that has been previously treated with platinum-based chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ, Jin WL. · · 2020 · cited 900× · PMID 32843638 · DOI 10.1038/s41392-020-00280-x

Verify or expand the search:

Other trials of Celecoxib

Trials testing the same drug.

NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
NCT07150949 — Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS · Phase 2 · recruiting
NCT07154316 — Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT06997068 — Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest U · Phase 2 · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Barbara Ann Karmanos Cancer Institute trials

Trials by the same sponsor.

NCT07343297 — Ask Questions About Clinical Trials · NA · not yet recruiting
NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
NCT07098299 — Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies · Phase 1 · recruiting
NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00030420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute
Last refreshed: 25 April 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00030420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing